Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Teva, Financial Levers, Paz Oil, Protalix: Israel Equity Movers

Israel’s TA-25 Index lost less than

0.1 percent to 1,251.14 at the 4:30 p.m. close in Tel Aviv. The following stocks rose or fell today. Symbols are in parentheses.

Africa-Israel Investments Ltd. (AFIL IT) increased 2.1 percent to 22.16 shekels, its biggest gain since July 7. The holding company’s Africa Israel Properties Ltd. unit said it completed a 840 million-shekel ($244 million) refinancing agreement for an office building in Tel Aviv.

Financial Levers Ltd. (LVR IT) slumped 8.5 percent to 0.75 shekel, its lowest price in 17 months. The investment company said that the Israel Securities Authority searched its offices on July 13 and confiscated documents.

Paz Oil Co. (PZOL IT) fell 0.9 percent to 570 shekels, the largest retreat since July 11. The maker of petroleum-based products said an International Air Transport Association report published on July 15 didn’t contain information finding the company at fault for contaminated jet fuel that stopped air traffic in Israel in early May.

Protalix BioTherapeutics Ltd. (PLX IT) decreased 2.8 percent to 23.30 shekels, the biggest decline since June 12. Biocell Ltd. (BCEL IT) slipped 1.6 percent to 29.35 shekels after saying its board decided to keep a 17 percent stake in the investment company.

Teva Pharmaceutical Industries Ltd. (TEVA IT) slid 2.6 percent to 165 shekels, its largest drop in four weeks. A U.S. district court found the world’s biggest maker of generic drugs infringed Amgen Inc. patents.

The court issued an injunction preventing Teva from selling its Neutroval treatment in the U.S. until Nov. 10, 2013, according to a PR Newswire statement. Teva also agreed not to sell its Neugranin medicine until the same date.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.